These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 7259531)

  • 21. Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients.
    Sommariva D; Tirrito M; Bonfiglioli D; Pogliaghi I; Branchi A; Cabrini E
    Int J Clin Pharmacol Res; 1986; 6(3):249-53. PubMed ID: 3744628
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A comparison of bezafibrate and clofibrate in type II B and type IV hyperlipoproteinemia].
    Bolzano K; Krempler F; Schellenberg B; Schlierf G
    Acta Med Austriaca; 1979; 6(3):90-4. PubMed ID: 547652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of various types of hyperlipoproteinaemia with a combination of Mg-chlorophenoxy-isobutyrate and mesoinositol-hexanicotinate (author's transl)].
    Bolzano K; Krempler F; Haslauer F
    Arzneimittelforschung; 1979; 29(10):1621-4. PubMed ID: 583231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of etofibrate retard, bezafibrate and procetofen.
    Luley C; Schwartzkopff W; Schilling A; Calder D; Scheffler W
    Artery; 1980; 8(2):128-33. PubMed ID: 7458677
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of pirozadil on lipids, lipoproteins and apolipoproteins in Japanese with type IIa hyperlipoproteinemia.
    Shinomiya M; Ishikawa Y; Shirai K; Saito Y; Yoshida S
    Arzneimittelforschung; 1987 Sep; 37(9):1069-71. PubMed ID: 3435604
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of hyperlipoproteinemia type II with Xantinol-nicotinate (author's transl)].
    Haacke H; Parwaresch MR; Mäder C
    Med Klin; 1977 Jul; 72(27):1183-7. PubMed ID: 196168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of ciprofibrate in primary type II and IV hyperlipidemia: the Italian multicenter study.
    Cattin L; Da Col PG; Feruglio FS; Finazzo L; Rimondi S; Descovich G; Manzato E; Zambon S; Crepaldi G; Siepi D
    Clin Ther; 1990; 12(6):482-8. PubMed ID: 2289217
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.
    Orö L; Olsson AG; Rössner S; Carlson LA
    Postgrad Med J; 1975; 51(8):suppl 76-81. PubMed ID: 215986
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of fibric acid derivatives on blood lipid and lipoprotein levels.
    Hunninghake DB; Peters JR
    Am J Med; 1987 Nov; 83(5B):44-9. PubMed ID: 3318453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of combination nicotinic acid and gemfibrozil treatment on intermediate density lipoprotein, and subclasses of low density lipoprotein and high density lipoprotein in patients with combined hyperlipidemia.
    Superko HR; Garrett BC; King SB; Momary KM; Chronos NA; Wood PD
    Am J Cardiol; 2009 Feb; 103(3):387-92. PubMed ID: 19166694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of colestipol and clofibrate, singly and in combination, on plasma lipid and lipoproteins in type IIb hyperlipoproteinemia.
    Hunninghake DB; Bell C; Olson L
    Metabolism; 1981 Jun; 30(6):610-5. PubMed ID: 7231198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dyslipidemias in patients with diabetes mellitus: classification and risks and benefits of therapy.
    Oki JC
    Pharmacotherapy; 1995; 15(3):317-37. PubMed ID: 7667166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Bezafibrate and delayed action etofibrate in hyperlipidemia].
    Lang PD; Vollmar J
    Dtsch Med Wochenschr; 1983 Feb; 108(8):302-5. PubMed ID: 6825604
    [No Abstract]   [Full Text] [Related]  

  • 34. [Effect of etofylline clofibrate on the composition of lipoproteins in hyperlipidaemia type IIb and IV (author's transl)].
    Ditschuneit HH; Hutt V; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1980; 30(11b):2063-7. PubMed ID: 7194061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect of diet and drug therapy on the level of high density lipoprotein cholesterol in patients with primary hyperlipoproteinemia].
    Padosh D; Kustosh D; Puchok I; Dem'ianova N; Audikovski M
    Klin Med (Mosk); 1981 Sep; 59(9):45-8. PubMed ID: 7311430
    [No Abstract]   [Full Text] [Related]  

  • 36. Lowering effect of fenofibrate (procetofene) on lipoproteins in different types of hyperlipoproteinemias.
    Canzler H; Bojanovski D
    Artery; 1980; 8(2):171-8. PubMed ID: 7458684
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Treatment of familial hypercholesterolemia with a combination of bezafibrate and guar.
    Wirth A; Middelhoff G; Braeuning C; Schlierf G
    Atherosclerosis; 1982 Dec; 45(3):291-7. PubMed ID: 7159500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The problem of type changes in hyperlipoproteinemia (type IIb, IV, V) under clofibrate and m-inositol nicotinate therapy].
    Schwartzkopff W; Zschiedrich M
    Verh Dtsch Ges Inn Med; 1976; 82 Pt 1():825-9. PubMed ID: 196436
    [No Abstract]   [Full Text] [Related]  

  • 39. [Efficacy of bezafibrate and fenofibrate on elevated blood lipids in HLP type IIa, IIb and IV].
    Schwartzkopff W; Luley C; Scheffler W; Lehmann-Leo W; Schilling A; Wegscheider K
    Med Welt; 1982 Apr; 33(17):631-7. PubMed ID: 7098826
    [No Abstract]   [Full Text] [Related]  

  • 40. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
    Hailer S; Pogarell O; Keller C; Wolfram G
    Arzneimittelforschung; 1996 Sep; 46(9):879-83. PubMed ID: 8876936
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.